Showing 6171-6180 of 9527 results for "".
Trends in the Medical Aesthetic Market
https://practicaldermatology.com/series/c-suite-chats/trends-in-the-medical-aesthetic-market/24560/Ethan Min, CEO of Benev, discusses trends in the medical aesthetic market, including the potential impact that Glucagon-like peptide-1 (GLP-1) for weight loss will have on the aesthetics industry.American Academy of Dermatology 2024
Meeting Wrap-Uphttps://practicaldermatology.com/cme/dermatology/meeting-coverage-aad-2024/24461/Practical Dermatology® was at the American Academy of Dermatology 2024 Annual Meeting in San Diego (AAD 2024) reporting on the latest research findings on innovative therapies and insights into managing complex dermatological disorders. From pioneering trials showcasing the efficacy of novel topicalPart 3, 1726 nm lasers: How to talk to patients about incorporating the 1726 nm wavelength lasers into their treatment regimens: Hint is to be patient
https://practicaldermatology.com/videos/scientifically-speaking/1726-nm-lasers-five-dermatologists-discuss-the-lasers-benefits-and-drawbacks-for-treating-acne-and-other-skin-conditions/24341/Chapter 3 of 7: David Goldberg, MD, from New York, Emil Tanghetti, MD, from Sacramento, Jordan Wang, MD, from Philadelphia and New York and Naz Saedi, MD, from Philadelphia talk about how to talk to patients about incorporating the 1726 nm wavelength lasers into their treatment regimens: Hint is toPart 4, 1726 nm lasers: Handling referred patients who are already on different treatment regimens
https://practicaldermatology.com/videos/scientifically-speaking/1726-nm-lasers-five-dermatologists-discuss-the-lasers-benefits-and-drawbacks-for-treating-acne-and-other-skin-conditions/24342/Chapter 4 of 7: David Goldberg, MD, from New York, Emil Tanghetti, MD, from Sacramento, Jordan Wang, MD, from Philadelphia and New York and Naz Saedi, MD, from Philadelphia talk about handling referred patients who are already on different treatment regimens.Active Vitiligo: What to Look For
https://practicaldermatology.com/videos/updates-vitiligo/active-vitiligo-what-to-look-for/24156/John E. Harris, MD, founding director of the Autoimmune Therapeutics Institute at the University of Massachusetts Chan Medical School, talks with Practical Dermatology Chief Medical Editor Neal Bhatia, MD, about the clinical signs of active vitiligo.DermWireTV: Atopic Dermatitis Guidelines, Derm Devices, and New Research
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-atopic-dermatitis-guidelines-derm-devices-and-new-research/20234/In this episode of DermWire TV, we report on the new atopic dermatitis guidelines, the long-term safety of upadacitinib, and novel energy-based dermatology devices. From the new at-home treatment for molluscum contagiosum to the discovery of genetic factors in early-onset Merkel cell carcinoma, thisArticles, Approvals, and Updates of 2023
https://practicaldermatology.com/topics/skin-cancer-photoprotection/articles-approvals-and-updates-of-2023/20231/Daniel Schlessinger, MD, provides his review of some of the year's most important articles, approvals, and updates, and describes how they relate to skin cancers, the first topical gene therapy, hidradenitis suppurativa treatment, and iPledge updates.Scientifically Speaking: Investing in Innovation with Humberto Antunes
https://practicaldermatology.com/videos/scientifically-speaking/scientifically-speaking-investing-in-innovation-with-humberto-antunes/20128/With decades of experience in dermatology and aesthetics, Humberto Antunes has helped to identify some key innovations in the field. Now part of Gore Range Capital, he continues to look for the next game-changer. He discusses his experience and shares insights on the specialties with host Joel L. CoDermWireTV: Novan EPI Acquisition, Champions for Change Gala, Mt. Sinai Alopecia Center
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-novan-epi-acquisition-champions-for-change-gala-mt-sinai-alopecia-center/20070/EPI Health is now a Novan company; the combined company will employ approximately 100 staff. Novan’s lead candidate, berdazimer gel 10.3%, performed well in a phase 3 study for the treatment of molluscum contagiosum. The Skin Cancer Foundation is gearing up for its signature fundraising event: The CDermWire TV: Adbry Approved; Syringoma Option; Confusion over Vaccines and Injectables
https://practicaldermatology.com/videos/dermwire-tv/dermwire-tv-adbry-approved-syringoma-option-confusion-over-vaccines-and-injectables/20041/Adbry (tralokinumab) from Leo Pharma is the newest biologic approved for moderate to severe atopic dermatitis in adults and is the first IL-13 blocker approved in the US. Pulse Bioscience’s nano-pulse stimulation (NPS) technology shows potential for the treatment of syringoma in a feasibility